What is new in SLE and APS
Over the past year, some important developments have taken place for the clinical approach to SLE. A multi-year large international initiative by the SLICC group resulted in the publication of a new set of classification criteria for SLE which, while not necessarily ‘better’ than the established ACR criteria, appear to have gained in face validity and seem to reflect some specific features of the diagnostic challenges surrounding this disease. In SLE therapeutics new analyses of the two phase III clinical trials with belimumab provided some guidance for clinicians as to which patients have the highest likelihood to benefit from this biologic. A large randomized trial of abatacept for lupus nephritis was reported as negative, but a post-hoc analysis demonstrated that the choice of endpoint in such trials can have a critical role in determining success or failure. Other biologics are currently in clinical trials, some with encouraging results. While progress in APS has not been as dramatic, some developments of interest have occurred.
In this lecture I will review the past year’s literature on SLE and APS with a primary focus on new findings that have immediate bearing on clinical practice when caring for such patients.
Disclosure of Interest R. Van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, BMS, GSK, Lilly, MSD, Pfizer, Roche, UCB